ARID2 and cutaneous melanoma: Additional biomarker examples for (E) diffuse large B-cell lymphoma (DLBCL) treated with nutlin-3a (MDM2 inhibitor) and stratified by TP53 mutants; (F) Low grade glioma (LGG) treated with daporinad (NAMPT inhibitor) and stratified by EGFR amplification; (G) Skin cutaneous melanoma (SKCM) treated with doramapimod (p38 and JNK2 inhibitor) and stratified with ARID2 mutations.